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ABSTRACT:
Introduction: Metoclopramide is a dopamine
receptor agonist and well known antiemetic and
gastrokynetic agent. Its usage has been restricted by Euro-
pean Medicines Agency (EMA), because of acute and
chronic neurological adverse events. Extrapyramidal syn-
dromes, including parkinsonism, tardive dyskinesia,
akathisia and acute dystonias, are the most reported and
most often drug side effects.
 Contingent and methods: We present a case of 23
years old woman with a 3-year history of Metoclopramide-
induced recurrent oculogyric crises.
Results: The patient suffered from examinophobia,
with minimal benzodiazepine symptoms relief. She
willfully took small dosages of oral Metoclopramide for
nausea relief before her examinations, which lead to recur-
rent oculogyric crises, short after the drug intake. After a
detailed explanation of drug side effects and  medicine dis-
continuation, they disappeared. She had no significant
medical and  family history of neurological and psychiat-
ric conditions. Laboratory data were normal.
Conclusions: Metoclopramide could induce acute or
chronic neurological conditions and its usage should be
restricted in general population to some specific conditions.
Some of its adverse reactions are often misdiagnosed and
improperly treated. Critical drug anamnesis with a focus
on Metoclopramide usage in some cases could enhance di-
agnosis.
Key words: Metoclopramide side effects, dopamine
antagonist, oculogyric crises.
INTRODUCTION:
Metoclopramide is well known antiemetic and
gastrokynetic agent, used for treatment of nausea, vomit-
ing, gastroparesis, gastro-esophageal reflux disease and
migraine [1, 2, 3, 4]. It is a dopamine (D2) receptor an-
tagonist with short life and mixed 5HT3 receptor antago-
nist and 5HT4 receptor agonist [5, 6, 7]. Although its sig-
nificant effect on nausea and vomiting and widely usage
in practice, on 24 October 2013 European Medicines
Agency’s Committee on Medical Products for Human Use
recommended changes of metoclopramide containing
medicines use, due to the potential risk of  serious neuro-
logical side effects. [8]
Extrapyramidal side effects due to metoclopamide
are the most common ones. Reported incidence is approxi-
mately 0.2%, but in aged and young patients this incidence
increases up to as high as 25%, the risk in children is 6
times higher than in adults [8, 9].
They may occur earlier after treatment (most often
within the first 24-72 hours), but most likely after several
dosages [8, 9, 10]. Risk factors for serious neurological
events are high dosages, long treatment period, and treat-
ment of children or elderly patients [8, 9, 10]. Tardive dys-
kinesia and Parkinsonism are generally seen after long-term
use, whereas dystonia and akathisia can occur after a sin-
gle dose of metoclopramide [10]. 
Although the possible reason of extrapyramidal side
effects presentation is a blockage of striatal D2 receptor,
their exact mechanism  remains unclear [9].
The most often types of extrapyramidal side effects
due to Metoclopramide usage are parkinsonism, tardive
dyskinesia, acute dystonias and akathisia. Metoclopramide-
induced parkinsonism is not uncommon, risk factors are
long-term usage, female sex, advanced age, diabetes
mellitus and polypharmacy [10, 11]. Tardive dyskinesia is
a syndrome characterized by persistent, potentially irrevers-
ible involuntary movements. Metoclopramide tardive dys-
kinesia incidence is likely to be <1%. [12, 13]. Risk fac-
tors are long term use of the medicine, increased age, fe-
male gender, pre-existing abnormal movements, diabetes
mellitus, “organic” brain dysfunction and atrophy, psychi-
atric disorders, family history of tardive dyskinesia,
polypragmasia [13]. Early syndrome recognition may im-
prove the likelihood of remission [14]; however the treat-
ment in some cases may be unsuccessful. Several medicines,
though with variable effects could be used for the symp-
toms relief; they are Amantadine, Tetrabenazine, Benzo-
diazepines (limited results), Melatonin (high dosages at
long treatment period could be effective), Vitamine E (lim-
ited results) [14]. Surgical interventions and Deep brain
stimulation may be used in treatment resistant cases [14].
Incidence of acute dystonias due to metoclopramide
is about 0.2% with female preponderance [15]. They are
usually presented as buccolingual, torticollic, oculogyric
and opisthotonic forms [15]. Risk factors are unclear, al-
though parenteral usage and high dosages are believed to
be more likely associated with acute dystonias [15]. The
mechanism of their development remains unclear, but the
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duration of these symptoms corresponds to T1/2 of the drug
[15]. Intravenous diphenhydramine may be used for dys-
tonia reversion [15, 16]. Sometimes the clinical picture may
imitate acute encephalitis or other brain diseases [15].
The incidence of metoclopramide – induced
akathisia is unknown, because of under recognition, al-
though it is believed to be about 20-25% [17, 18]. It may
present with varying grades of severity [17, 18]. Benzodia-
zepines, betablockers, α2-agonists, opioids, and anti-
cholinergics may be used for treating syndrome [17, 18].
CONTINGENT AND METHODS:
We present a case of 23 years old woman with Meto-
clopramide-induced oculogyric crises misdiagnosed as
panic attacks. History of disease, general, neurological and
psychological examinations, laboratory data are applied.
RESULTS:
The patient (23 years old student) was presented at
our department with a 3- year history of unexplained ocu-
logyric crises during some of her examinations. She suf-
fered from long term examinophobia with anxiety and mod-
erate autonomic signs, including nausea and vomiting,
tachycardia and pallor. Small dosage of benzodiazepine
(Rivotril) for acute symptom prevention was prescribed
with minimal effect and she willfully stopped it. At first
she complained of unexpected oculogyric crises with short
duration (2 minutes), during her examination 3 years ago.
This sign troubled her and she visited her outpatient psy-
chiatrist, who diagnosed severe panic attack and sent her
to psychologist. Psychotherapy was not conducted, because
of patient’s refusal. The same syndrome she had many times,
irregularly, during some of her examinations, however the
syndrome worsened with every appearance – the duration
and severity of signs increased and she was unable to sit
for her exams. She had no symptoms between examinations,
no other significant medical or family history. At first she
denied substance abuse and unprescribed medicine usage.
Laboratory data were normal. She was kindly asked again
for using unprescribed medications of all kinds, with a fo-
cus on dopamine-agonists. The patient confessed that she
had taken 1 or 2 tablets (10-20 mg) Metoclopramide be-
fore examinations for nausea suppression. Metoclopramide
side effects were explained to the patient and the medica-
tion was discontinued. Proton-pump inhibitor was pre-
scribed for her nausea; she refused benzodiapine treatment
and psychotherapy. The patient had no more oculogyric cri-
ses after the previously mentioned corrections and she
passed her exams session with success.
DISCUSSION:
Oculogyric crisis is an acute dystonic reaction [15],
characterized by prolonged involuntary upward deviation
of the eyes, which can be associated with some drugs us-
age - neuroleptics and other dopamine antagonist (includ-
ing Metoclopramide), carbamazepine, chloroquine,
cisplatin, lithium, domperidone, nifedipine, pemoline,
phencyclidine, etc. or with brain diseases. It could be re-
current and triggered by different factors (including stress
and drug exposure). The syndrome is often misdisgnosed.
In many cases it can mimic some neurological and psychi-
atric diseases, particularly in cases with short duration and
mild severity, it is underdiagnosed [15]. Our patient had
long history of recurrent acute Metoclopramide-induced
oculogyric crises, misdiagnosed as panic attacks, with wors-
ening of signs that lead to severe, although short-time func-
tional disabilities and psychological distress. The signs
occurred early after taking medication and disappeared
without treatment, similarly to that notified by Arumugam
[15]. Our patient had other psychiatric illness –
examinophobia, but no history of co-morbid neurological
and psychiatric conditions, no family history of dyskinesia
or other neurological diseases and no polypragmasia. The
explanation of drug-side effects to the patient appeared to
be of great importance, because, because she obviously
took and stopped medications herself, without visiting phy-
sician or reading drug instructions. In this clinical case we
diagnosed the Metoclopramide – induced adverse drug re-
action after a 2- month clear period and no oculogyric cri-
ses during the whole exams session. The patient remained
under medical observation and according to us should un-
dergo a psychological treatment.
CONCLUSIONS:
Metoclopramide induces acute or chronic neurologi-
cal side effects and its usage in general population should
be restricted to some specific conditions. Some of its ad-
verse reactions are often misdiagnosed and improperly
treated. In some cases the thorough drug history with a fo-
cus on Metoclopramide usage enhances diagnosis.
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